306 related articles for article (PubMed ID: 15701824)
1. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
Doolittle ND; Abrey LE; Bleyer WA; Brem S; Davis TP; Dore-Duffy P; Drewes LR; Hall WA; Hoffman JM; Korfel A; Martuza R; Muldoon LL; Peereboom D; Peterson DR; Rabkin SD; Smith Q; Stevens GH; Neuwelt EA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):421-8. PubMed ID: 15701824
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
[TBL] [Abstract][Full Text] [Related]
3. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.
Doolittle ND; Peereboom DM; Christoforidis GA; Hall WA; Palmieri D; Brock PR; Campbell KC; Dickey DT; Muldoon LL; O'Neill BP; Peterson DR; Pollock B; Soussain C; Smith Q; Tyson RM; Neuwelt EA
J Neurooncol; 2007 Jan; 81(1):81-91. PubMed ID: 16858513
[TBL] [Abstract][Full Text] [Related]
4. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
5. Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.
Papademetriou IT; Porter T
Ther Deliv; 2015; 6(8):989-1016. PubMed ID: 26488496
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier disruption in the treatment of brain tumors.
Blanchette M; Fortin D
Methods Mol Biol; 2011; 686():447-63. PubMed ID: 21082387
[TBL] [Abstract][Full Text] [Related]
7. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
Muldoon LL; Tratnyek PG; Jacobs PM; Doolittle ND; Christoforidis GA; Frank JA; Lindau M; Lockman PR; Manninger SP; Qiang Y; Spence AM; Stupp SI; Zhang M; Neuwelt EA
AJNR Am J Neuroradiol; 2006 Mar; 27(3):715-21. PubMed ID: 16552023
[TBL] [Abstract][Full Text] [Related]
8. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
Parrish KE; Sarkaria JN; Elmquist WF
Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
[TBL] [Abstract][Full Text] [Related]
9. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.
Arvanitis CD; Ferraro GB; Jain RK
Nat Rev Cancer; 2020 Jan; 20(1):26-41. PubMed ID: 31601988
[TBL] [Abstract][Full Text] [Related]
10. Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status.
Liu HL; Yang HW; Hua MY; Wei KC
Neurosurg Focus; 2012 Jan; 32(1):E4. PubMed ID: 22208897
[TBL] [Abstract][Full Text] [Related]
11. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors.
Haluska M; Anthony ML
Clin J Oncol Nurs; 2004 Jun; 8(3):263-7. PubMed ID: 15208820
[TBL] [Abstract][Full Text] [Related]
12. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J; Agrahari V; Youm I
J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
14. Blood-Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade.
Virtanen PS; Ortiz KJ; Patel A; Blocher WA; Richardson AM
Curr Oncol Rep; 2024 Mar; 26(3):236-249. PubMed ID: 38329660
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
16. [The blood-brain barrier should not be underestimated in neuro-oncology].
Fortin D
Rev Neurol (Paris); 2004 May; 160(5 Pt 1):523-32. PubMed ID: 15269669
[TBL] [Abstract][Full Text] [Related]
17. Blood-brain barrier and treatment of central nervous system tumors.
Wiranowska M
J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453
[TBL] [Abstract][Full Text] [Related]
18. Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors.
Cooper I; Last D; Guez D; Sharabi S; Elhaik Goldman S; Lubitz I; Daniels D; Salomon S; Tamar G; Tamir T; Mardor R; Fridkin M; Shechter Y; Mardor Y
J Cereb Blood Flow Metab; 2015 Jun; 35(6):967-76. PubMed ID: 25669901
[TBL] [Abstract][Full Text] [Related]
19. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
Juillerat-Jeanneret L
Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
[TBL] [Abstract][Full Text] [Related]
20. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
